Ibex Medical Analytics, a Tel Aviv, Israel-based company advancing AI-powered cancer diagnostics, raised $55M in Series C funding.
The round, which brought the total amount to $100M since its inception in 2016, was led by 83North. Other participants included Sienna Venture Capital and existing investors in the company, Octopus Ventures, aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital.
The company intends to use the funds to expand its presence in the United States to meet the increasing demand for AI-powered diagnostic solutions, and to accelerate the growth of its product portfolio.
Led by CEO Joseph Mossel, Ibex Medical Analytics empowers cancer diagnostics with clinical grade AI-powered solutions to provide personalized cancer diagnosis for every patient. Its Galen suite of solutions is deployed AI-technology in pathology and is used as part of everyday routine, supporting pathologists and providers worldwide in improving the quality and accuracy of diagnosis, implementing comprehensive quality control, reducing turnaround times and boosting productivity with more efficient workflows. Ibex’s Artificial Intelligence technology is built on deep learning algorithms trained by a team of pathologists, data scientists and software engineers.
The Galen™ platform includes certain solutions which are CE marked and registered with the UK MHRA. The solutions are for Research Use Only (RUO) in the United States and not cleared by the FDA.
FinSMEs
06/09/2023